tyrosine/stroke

FIELD OF THE INVENTION This invention relates to substituted compounds of formula (I): ##STR2## wherein Ar.sub.1, X, Y, P, Q and Het are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell

FIELD OF THE INVENTION This invention relates to substituted compounds of formula (I): ##STR2## wherein Ar.sub.1, X, Y, P, Q and Het are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell

TECHNICAL FIELD OF THE INVENTION This invention relates to substituted compounds of formula (I): ##STR2## wherein Ar.sub.1, R.sub.a, R.sub.4, R.sub.5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting

TECHNICAL FIELD OF THE INVENTION This invention relates to substituted compounds of formula (I): ##STR2## wherein Ar.sub.1, R.sub.a, R.sub.4, R.sub.5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting

This application claims priority to IT Patent Application No. TO2014A000806 filed Oct. 8, 2014, the entire content of which is hereby incorporated by reference. FIELD OF THE INVENTION The present description relates to compositions for use in the treatment of stroke in patients, particularly

FIELD OF THE INVENTION The present invention relates to quinoline derivatives and to the use thereof in therapy. More particularly, the present invention relates to quinoline derivatives for the treatment of cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke,

FIELD OF THE INVENTION The present invention relates to quinoline derivatives and to the use thereof in therapy. More particularly, the present invention relates to quinoline derivatives for the treatment of cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke,

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to compounds that act to block calcium channels; methods of using the compounds to treat stroke, cerebral ischemia, pain, head trauma, or epilepsy; and to pharmaceutical compositions that contain the compounds of the

CROSS REFERENCE This application is a 371 of PCT/US99/12276 filed Jun. 2, 1999. BACKGROUND OF THE INVENTION FIELD OF THE INVENTION The present invention relates to compounds that act to block calcium channels; methods of using the compounds to treat stroke, cerebral ischemia, pain, head trauma, or

TECHNICAL FIELD The present invention relates generally to techniques for manipulating embryonic stem cells. More specifically, the invention relates to a method for derivation of neural stem cells (NSCs) from embryonic stem cells (ESCs) and the use of the ESC-derived NSCs to treat various neural

SEQUENCE LISTING A sequence listing is submitted with the present application. The sequence listing is submitted as a .txt file entitled 7120107_SEQ_ST25.txt and is 12 kb in size. The entire contents of the sequence listing are hereby incorporated by reference. BACKGROUND Brain injury resulting from

SEQUENCE LISTING A sequence listing is submitted with the present application. The sequence listing is submitted as a .txt file entitled 7120102_SEQ_ST25.txt and is 12 kb in size. The entire contents of the sequence listing are hereby incorporated by reference. BACKGROUND Brain injury resulting from

SEQUENCE LISTING A sequence listing is submitted with the present application. The sequence listing is submitted as a .txt file entitled 7120107_SEQ_ST25.txt and is 12 kb in size. The entire contents of the sequence listing are hereby incorporated by reference. BACKGROUND Brain injury resulting from

FIELD OF THE INVENTION The invention relates to the field of bioorganic chemistry, namely to novel substituted dipeptides that are mimetics of the neurotrophic factors, which can be useful as pharmaceutical agents for the regulation of growth, differentiation, survival and programmed neuronal cell

The present invention relates to novel synergistic pharmaceutical compositions and to a method for the treatment of certain neurological disorders in mammals including man. More particularly, the invention relates to novel pharmaceutical compositions and a method for alleviating ailments caused by a